A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder

• Published in: Journal of clinical psychopharmacology Vol. 32; no. 4; p. 551
• Main Authors: Ibrahim, Lobna, Diaz Granados, Nancy, Jolkovsky, Libby, Brutsche, Nancy, Luckenbaugh, David A, Herring, W Joseph, Potter, William Z, Zarate, Jr, Carlos A
• Format: Journal Article
• Language: English
• Published: United States 01.08.2012
• Subjects: Administration, Oral; Adolescent; Adult; Antidepressive Agents - therapeutic use; Brain-Derived Neurotrophic Factor - blood; Cross-Over Studies; Depressive Disorder, Treatment-Resistant - blood; Depressive Disorder, Treatment-Resistant - drug therapy; Female; Humans; Male; Middle Aged; Pilot Projects; Piperidines - administration & dosage; Piperidines - adverse effects; Piperidines - blood; Piperidines - therapeutic use; Psychiatric Status Rating Scales - statistics & numerical data; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - blood; Pyrimidines - therapeutic use; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors

Converging lines of evidence suggest that the glutamatergic system may play an increasingly important role in the development of novel therapeutics for major depressive disorder (MDD), particularly agents associated with rapid antidepressant effects. Diverse glutamatergic modulators targeting N-meth...